{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-034544","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.518001+00:00","generated_at":"2026-06-09T21:55:12.953730+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint","bullets":["Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).","Organic base-business sales (ex-COVID tests) up 13.8%; double-digit growth in all four segments.","Full-year 2023 adjusted EPS guidance raised to $4.42–$4.46 (midpoint $4.44 vs prior $4.30–$4.50).","Medical Devices organic growth 14.7%; FreeStyle Libre sales $1.4B (+28.5% organic).","Quarterly dividend maintained at $0.51/share; 399th consecutive quarterly payout."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-034544","json":"https://secwatch.observer/filing/0001628280-23-034544.json","markdown":"https://secwatch.observer/filing/0001628280-23-034544.md","text":"https://secwatch.observer/filing/0001628280-23-034544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/0001628280-23-034544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/abt-20231018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:55:12.953730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"486ec9f5f9787cc28ecc63435fa34263d503ff1b","claim":"ABBOTT LABORATORIES updated its third quarter ended Sept. 30, 2023 guidance (raised).","evidence_excerpt":"Abbott today announced financial results for the third quarter ended Sept. 30, 2023. • Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. • Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and projects adjusted diluted EPS of $4.42 to $4.46, which represents an increase at the midpoint of the guidance range.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828023034544/0001628280-23-034544-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended Sept. 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}